This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=117 http://www.lsis.com/goto/r117/rss 2012-02-05T11:11:14+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 Diabetes Self Manag. |-| Hieronymus L, Velasco K. |-| Amylin Pharmaceuticals, Inc., San Diego, California, USA. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 Aims. Amylinergic and melanocortinergic systems have each been implicated in energy balance regulation. We examined the interactive effects of both systems using gene knockout and pharmacological approaches. Methods. Acute food consumption studies in overnight fasted male wild-type (WT) and melanocortin-4 receptor (MC4-R) deficient rats and in male and female WT and amylin knockout mice (AmyKO). Changes in food intake, body weight and composition in male WT and MC4-R deficient rats and in male (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 Aims Antibody formation to therapeutic peptides is common. This analysis characterizes the time-course and cross-reactivity of anti-exenatide antibodies and potential effects on efficacy and safety. Materials and Methods Data from ITT patients in 12 controlled (n=2225, 12-52wks) and 5 uncontrolled (n=1538, up to 3yrs) exenatide BID trials and 4 controlled (n=653, 24-30wks) exenatide once weekly (QW) trials with 1 uncontrolled period (n=128, 52wks) were analyzed. Results Mean titers peaked (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=117 The U.K.'s health-care cost-effectiveness body Friday confirmed initial guidance recommending Eli Lilly & Co. (LLY) and Amylin Pharmaceuticals Inc.'s (AMLN) Type 2 diabetes drug Bydureon for use in the U.K.'s publicly funded National Health Service. In final guidance, the National Institute for Health and Clinical Excellence, or NICE, said the injectable medicine, known generically as exenatide, could be given in combination with certain other drugs in obese patients with a body mass index (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 Glucagon-like peptide-1 (GLP-1), a gut derived hormone secreted in response to nutrients, has several glucose and weight regulating actions including enhancement of glucose stimulated insulin secretion, suppression of glucagon secretion, slowing of gastric emptying, and reduction in food intake. Due to these multiple effects, the GLP-1 receptor system has become an attractive target for type 2 diabetes therapies. However, GLP-1 has significant limitations as a therapeutic due to its rapid (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=117 POWAY, CA-(Marketwire - January 04, 2012) - Digirad Corporation (NASDAQ: DRAD) today announced that Sarah L. Hanssen has been named Senior Vice President of Strategic Marketing and Business Development, effective December 31, 2011. Hanssen reports directly to Chief Executive Officer Todd P. Clyde. Hanssen, 48, a resident of San Diego, has more than 15 years of experience in driving growth via strategic marketing, business integration, operations and business development for global, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 Diabetes Self Manag. |-| Hieronymus L. |-| Amylin Pharmaceuticals, Inc. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=117 United States Patent: 8076288 |-| Title: Hybrid polypeptides having glucose lowering activity |-| Inventors: Levy; Odile Esther (San Diego, CA), Hanley; Michael R. (Corte Madera, CA), Jodka; Carolyn M. (Encinitas, CA), Lewis; Diana Y. (San Diego, CA), Soares; Christopher J. (La Jolla, CA), Ghosh; Soumitra S. (San Diego, CA), D'Souza; Lawrence J. (San Diego, CA), Parkes; David G. (Del Mar, CA), Mack; Christine M. (San Diego, CA) |-| Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA) |-| The (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 Aim: The objective of this systematic review was to assess the published literature on the effectiveness of exenatide BID (exenatide) in clinical practice, specifically its effects on hemoglobin A1C (A1C), fasting glucose (FG), weight, systolic blood pressure (SBP), medication use, hospitalization, and cardiovascular disease (CVD) outcomes. Methods: A systematic literature search using the MEDLINE database of English language literature published between January 2005 and May 2011 was (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 OBJECTIVE - Treatment with an analog of human leptin, metreleptin, has been shown to benefit the metabolic abnormalities in patients with rare syndromes of inherited or acquired lipodystrophy. The objective of this analysis was to evaluate the long-term clinical effect of metreleptin on glycemic and lipid abnormalities and markers of hepatic steatosis in patients with lipodystrophy.METHODS - Fifty-five patients (36 generalized lipodystrophy, 19 partial lipodystrophy) with at least 1 of 3 (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=117 DURHAM, N.C., Nov. 4, 2011 /PRNewswire/ - NeuroCog Trials, Inc. today announced the appointment of Michael R. Hufford, Ph.D. to the position of Chief Operating Officer. In this newly created position, Dr. Hufford will assume responsibility for the continued growth and expansion of NeuroCog Trials' business, research and development, and operations. "The investment in research and development for pro-cognitive therapies across a wide variety of therapeutic areas has never been stronger. As (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 DUBLIN-(BUSINESS WIRE)-Alkermes plc (NASDAQ: ALKS) today reported financial results for its second quarter of fiscal 2012, which ended on Sept. 30, 2011. These are the first financial results released by Alkermes plc (Alkermes) following the successful completion on Sept. 16, 2011, of the merger of Alkermes, Inc. with Elan Drug Technologies (EDT). Alkermes is a new, growing, global leader in central nervous system (CNS) therapeutics, characterized by its broad portfolio of commercial (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=117 Byetta (exenatide) injection has been approved by the FDA as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without. A pivotal study found that with exenatide patients achieved better glycemic control without gaining weight or increased hypoglycemia risk, compared to those on just (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 AIMS/HYPOTHESIS: Systemic fibroblast growth factor (FGF)21 levels and hepatic FGF21 production are increased in non-alcoholic fatty liver disease patients, suggesting FGF21 resistance. We examined the effects of exenatide on FGF21 in patients with type 2 diabetes and in a diet-induced mouse model of obesity (DIO). METHODS: Type 2 diabetes mellitus patients (n?=?24) on diet and/or metformin were randomised (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=117 United States Patent: 8026210 |-| Title: Exendins and exendin agonist analogs to regulate gastrointestinal motility |-| Inventors: Young; Andrew A. (Rancho Santa Fe, CA), Gedulin; Bronislava (Del Mar, CA) |-| Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA) |-| Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 CAMBRIDGE, Mass.-(BUSINESS WIRE)-Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced the appointment of Dennis Kim, M.D., M.B.A., to the position of chief medical officer. In this newly created position, Dr. Kim will assume primary responsibility for Zafgen s clinical development, including clinical and regulatory strategy, trial design and oversight (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=117 ScienceDaily (Sep. 16, 2011) Two newer drugs used to treat Type 2 diabetes could be linked to a significantly increased risk of developing pancreatitis and pancreatic cancer, and one could also be linked to an increased risk of thyroid cancer, according to a new UCLA study. See Also: Health & Medicine Pancreatic Cancer Diabetes Colon Cancer Cancer Lung Cancer Breast Cancer Reference Diabetes mellitus type 1 Health benefits of tea Clinical trial Diabetes mellitus type 2 Researchers from the (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=117 Two newer drugs used to treat Type 2 diabetes could be linked to a significantly increased risk of developing pancreatitis and pancreatic cancer, and one could also be linked to an increased risk of thyroid cancer, according to a new UCLA study. Researchers from the Larry L. Hillblom Islet Research Center at UCLA examined the U.S. Food and Drug Administration's database for adverse events reported between 2004 and 2009 among patients using the drugs sitagliptin and exenatide. They found a (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=117 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) announced new analyses from the DURATION-3 and -4 trials demonstrating patients treated with the investigational medication BYDUREON (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments. The analyses showed that patients (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=117 Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly & Co. (LLY) s Byetta medicine and Novo Nordisk A/S s Victoza face scrutiny after some researchers warned that prolonged use of the insulin-raising treatments may make diabetics more vulnerable to cancers. A debate on the potential dangers of GLP-1 therapies, the class of drugs to which Byetta and Victoza belong, will be a highlight of the European Association for the Study of Diabetes conference in Lisbon this week. A review of a database of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 LISBON, Portugal-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced new analyses from the DURATION-3 and -4 trials demonstrating patients treated with the investigational medication BYDUREON ¢ (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=117 LISBON, Portugal-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced new analyses from the DURATION-3 and -4 trials demonstrating patients treated with the investigational medication BYDUREON ¢ (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=117 United States Patent: 8008255 |-| Title: Methods and compositions for enhanced transmucosal delivery of peptides and proteins |-| Inventors: Ong; John (San Marcos, CA), Jennings; Robert (San Diego, CA), Stetsko; Gregg (San Diego, CA) |-| Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA) |-| Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 WALTHAM, Mass.-(BUSINESS WIRE)-Alkermes, Inc. (NASDAQ: ALKS) today announced that Alkermes shareholders have approved the merger of Alkermes and Elan Drug Technologies ( œEDT ), the profitable drug formulation and manufacturing business unit of Elan Corporation, plc (NYSE: ELN) ( œElan ). Both businesses will be combined under Alkermes plc, a newly formed company domiciled in Ireland. Approximately 99.9% of the votes cast by Alkermes shareholders were in favor of adopting the business (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 MENLO PARK, Calif.-(BUSINESS WIRE)-MedtechWomen today announced that registration is open for MedtechVision 2011, the first-ever conference designed by and for women on the forefront of medical innovation. The conference will be held September 15 and 16, 2011, at the Rosewood Sand Hill in Menlo Park, Calif. A discount of $250 is available for conference attendees who register on or before August 19, 2011. We look forward to bringing together the many women leaders in medical devices and (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=117 United States Patent: 7981861 |-| Title: Method of performing angioplasty with a GLP-1 molecule |-| Inventors: Coolidge; Thomas R. (Falls Village, CT), Ehlers; Mario (Lincoln, NE) |-| Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA) |-| The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=117 The U.S. Food and Drug Administration has set a Jan. 28, 2012 deadline for its review of a diabetes drug being developed by Amylin Pharmaceuticals Inc (AMLN.O), Eli Lilly and Co (LLY.N) and Alkermes Inc (ALKS.O). The companies submitted an application for the drug, Bydureon, last month after the regulatory agency declined on two separate occasions to approve it. The FDA asked last year for more data on Bydureon's impact on the heart before deciding whether to clear it as a treatment for Type 2 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 SAN DIEGO, INDIANAPOLIS & WALTHAM, Mass.-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the companies BYDUREON ¢ (exenatide extended-release for injectable suspension) resubmission. The FDA has categorized it as a Class 2 resubmission requiring up to six months for review and assigned a new Prescription Drug User Fee Act (PDUFA) (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/channels/?query=117 Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that they are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity that comprises pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin. The joint decision was based on a commercial reassessment of the pramlintide/metreleptin program, which had been in Phase 2 development as a twice-a-day (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 WALTHAM, Mass.-(BUSINESS WIRE)-Alkermes, Inc. (NASDAQ: ALKS) today reported financial results for its first quarter of fiscal 2012, which ended on June 30, 2011. We will continue to prudently manage our expenses and focus on top line growth to achieve the financial expectations we have set forth for Alkermes plc. Quarterly financial highlights: Announcement of financially transformative merger agreement with Elan Drug Technologies (EDT) that is expected to close in September 2011. Revenues (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 SAN DIEGO, INDIANAPOLIS & WALTHAM, Mass.-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the companies have submitted their reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON ¢ (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes. The companies expect to receive an (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Peptide Analysis database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 139,000 individuals working in Peptide Analysis. http:/bit.ly/rhNBwk. Top 10 Countries for Peptide Analysis (ranked by number of senior researchers) United States Of America (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 WALTHAM, Mass.-(BUSINESS WIRE)-Alkermes, Inc. (NASDAQ: ALKS) today will host its Analyst and Investor Day from 3:00-5:00 p.m. Eastern Time at the Boston Harbor Hotel in Boston. It will be a dramatically different company, with a broad portfolio of diverse and significant commercial products and pipeline candidates to drive growth and profitability. Alkermes will discuss the business strategy and financial outlook related to the merger of Alkermes with Elan Drug Technologies (EDT) to create (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 Abstract Exenatide once-weekly (EQW [2?mg s.c.]) is under development as monotherapy as an adjunct to diet and exercise or as a combination therapy with an oral antidiabetes drug(s) in adults with type 2 diabetes. This long-acting formulation contains the active ingredient of the original exenatide twice-daily (EBID) formulation encapsulated in 0.06-mm-diameter microspheres of medical-grade poly-(d,l-lactide-co-glycolide) (PLG). After mechanical suspension and subcutaneous injection by the (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=117 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma concentrations. The study was conducted to satisfy a requirement by the U.S. Food and Drug Administration (FDA) in support of the New Drug Application (NDA) for BYDUREON (exenatide extended-release for injectable suspension), an (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 Davalintide is a second generation amylinomimetic peptide possessing enhanced pharmacological properties over rat amylin to reduce food intake in preclinical models. The current experiments in rats describe additional glucoregulatory actions of davalintide consistent with amylin agonism, and explore the duration of action of these effects. Subcutaneous (SC) injection of davalintide slowed gastric emptying with equal potency to amylin (ED(50) 's=2.3 and 4.1 ?g/kg). This effect was maintained (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 Abstract In patients with type 2 diabetes mellitus (T2DM), the physiologic glucagon-like peptide-1 (GLP-1) response, which is involved in glucose regulation through several mechanisms, is dysfunctional. GLP-1 receptor agonists can fill an unmet therapeutic need in the treatment of T2DM: improving glycemic control without increasing the risk of hypoglycemia (except with concomitant sulfonylureas) and reducing weight in a substantial proportion of patients. GLP-1 receptor agonists have impacted (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma concentrations. The study was conducted to satisfy a requirement by the U.S. Food and Drug Administration (FDA) in support of the New Drug Application (NDA) for BYDUREON (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=117 The Food and Drug Administration, often the center of attention for the U.S. biotech and medical device industries, came under the spotlight a bit more this week amid talk of changing the agency s mission statement. There also was news from Amylin that should address at least some concerns FDA regulators have raised about its once-a-week treatment for diabetes. Shares of San Diego s Amylin Pharmaceuticals (NASDAQ: AMLN) have gained more than 13 percent since Friday, when the company said its (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 Incretin-based therapies have established a foothold in the diabetes armamentarium through the introduction of oral agents, the DPP-4 inhibitors, and the injectable class, the GLP-1 receptor agonists. In 2009, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) authored a revised consensus algorithm for the initiation and adjustment of therapy in type 2 diabetes. The revised algorithm accounts for the entry of incretin-based therapies into common (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Peptide Synthesis database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 52,000 individuals working in Peptide Synthesis. http:/bit.ly/k1o3F7. Top 10 Countries for Peptide Synthesis Research (ranked by number of senior researchers) United States (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=117 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced data from a new analysis characterizing the effects of SYMLIN (pramlintide acetate) injection in patients with type 1 diabetes who used insulin pumps during two previously completed clinical studies. The data, which will be presented during a poster presentation at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego, demonstrated that SYMLIN helped reduce A1C (a measure of average blood sugar over three (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=117 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) announced results from an analysis of the DURATION-1 study that showed the investigational type 2 diabetes medication BYDUREON (exenatide extended-release for injectable suspension) was not associated with clinically relevant QT prolongation in patients with type 2 diabetes. These findings will be presented in a poster session at the 71st Scientific Sessions of the American Diabetes (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 SAN DIEGO-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced additional results from a phase 2 study of an investigational, once-monthly injectable suspension formulation of exenatide which showed substantial improvements in glycemic control, including reductions in A1C and fasting plasma glucose, with modest weight loss. These findings will be presented in a late breaking poster session at the 71st (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 SAN DIEGO-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from an analysis of the DURATION-1 study that showed the investigational type 2 diabetes medication BYDUREON ¢ (exenatide extended-release for injectable suspension) was not associated with clinically relevant QT prolongation in patients with type 2 diabetes. These findings will be presented in a poster session at the 71st (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 SAN DIEGO-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from long-term extensions of the DURATION-1 and 3 studies evaluating BYDUREON ¢ (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes. The studies will be presented at the 71st Scientific Sessions of the American Diabetes Association. Faced with the progressive nature of type 2 (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=117 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidates BYDUREON (exenatide extended-release for injectable suspension) and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28. The Company will also (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 INDIANAPOLIS, SAN DIEGO & WALTHAM, Mass.-(BUSINESS WIRE)-Eli Lilly and Company (NYSE: LLY), together with Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes, Inc. (Nasdaq: ALKS), announced today that the European Commission has granted marketing authorization to BYDUREON ¢ (exenatide 2 mg powder and solvent for prolonged release suspension for injection). BYDUREON is the first and only once-weekly treatment for type 2 diabetes and has demonstrated powerful efficacy in multiple (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=117 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/a3f3a7/global_biotechnolo) has announced the addition of the "Global Biotechnology Market" report to their offering. Biotechnology has become the foundation on which the pharmaceutical industry and many others are progressing on. The biotech revolution has surpassed the IT revolution as well and has become the new engine of the global economy. The products derived through biotechnology have altered the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=117 The discoveries of the incretin hormone glucagon-like peptide-1 (GLP-1) and the ?-cell hormone amylin have translated into hormone-based therapies for diabetes. Both classes of molecules also exhibit weight-lowering effects and have been investigated for their anti-obesity potential. In the present review, we explore the mechanisms underlying the physiological and pharmacological actions of GLP-1 and amylin agonism. Despite their similarities (e.g., both molecular classes slow gastric (…)